Pharma And Healthcare Firms Brace For Margin Squeeze, Says HDFC Securities

The brokerage’s latest sectoral outlook highlights that despite strong demand fundamentals, cost escalations and pricing constraints will continue to challenge earnings growth. Investors and industry stakeholders are advised to monitor operational efficiencies and evolving policy frameworks closely.  

Key Highlights

• Pharma and healthcare companies face continued margin pressure  
• Rising input costs and regulatory challenges weigh on profitability  
• API costs and compliance expenses add financial strain  
• Drug pricing regulations restrict cost pass-through  
• Diversified portfolios and exports seen as resilience factors